Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib. Luo Y, Wei J, Zhang J, Zeng L, et al. Lung Cancer 2021;155:170-174.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Luo Y, Wei J, Zhang J, Zeng L, et al. Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib. Lung Cancer 2021;155:170-174.
PMID: 33838468